Literature DB >> 21403039

Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.

Daniel P Alford1, Colleen T LaBelle, Natalie Kretsch, Alexis Bergeron, Michael Winter, Michael Botticelli, Jeffrey H Samet.   

Abstract

BACKGROUND: Opioid addiction is a chronic disease treatable in primary care settings with buprenorphine hydrochloride, but this treatment remains underused. We describe a collaborative care model for managing opioid addiction with buprenorphine hydrochloride-naloxone hydrochloride dihydrate sublingual tablets.
METHODS: Ours is a cohort study of patients treated for opioid addiction using collaborative care between nurse care managers and generalist physicians in an urban academic primary care practice during a 5-year period. We examine patient characteristics, 12-month treatment success (ie, retention or taper after 6 months), and predictors of successful outcomes.
RESULTS: From September 1, 2003, through September 30, 2008, 408 patients with opioid addiction were treated with buprenorphine. Twenty-six patients were excluded from analysis because they left treatment owing to preexisting legal or medical conditions or a need to transfer to another buprenorphine program. At 1 year, 196 of 382 patients (51.3%) underwent successful treatment. Of patients remaining in treatment at 12 months, 154 of 169 (91.1%) were no longer using illicit opioids or cocaine based on urine drug test results. On admission, patients who were older, were employed, and used illicit buprenorphine had significantly higher odds of treatment success; those of African American or Hispanic/Latino race had significantly lower odds of treatment success. These outcomes were achieved with a model that facilitated physician involvement.
CONCLUSION: Collaborative care with nurse care managers in an urban primary care practice is an alternative and successful treatment method for most patients with opioid addiction that makes effective use of time for physicians who prescribe buprenorphine. ©2011 American Medical Association. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403039      PMCID: PMC3059544          DOI: 10.1001/archinternmed.2010.541

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  23 in total

1.  Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Authors:  Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

Review 2.  Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.

Authors: 
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

3.  Buprenorphine treatment in an urban community health center: what to expect.

Authors:  Chinazo Cunningham; Angela Giovanniello; Galit Sacajiu; Susan Whitley; Pamela Mund; Robert Beil; Nancy Sohler
Journal:  Fam Med       Date:  2008 Jul-Aug       Impact factor: 1.756

4.  Exposure to opioid maintenance treatment reduces long-term mortality.

Authors:  Amy Gibson; Louisa Degenhardt; Richard P Mattick; Robert Ali; Jason White; Susannah O'Brien
Journal:  Addiction       Date:  2008-01-08       Impact factor: 6.526

Review 5.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

6.  The case for chronic disease management for addiction.

Authors:  Richard Saitz; Mary Jo Larson; Colleen Labelle; Jessica Richardson; Jeffrey H Samet
Journal:  J Addict Med       Date:  2008-06       Impact factor: 3.702

7.  Integrating systematic chronic care for diabetes into an academic general internal medicine resident-faculty practice.

Authors:  Albert DiPiero; David A Dorr; Christine Kelso; Judith L Bowen
Journal:  J Gen Intern Med       Date:  2008-08-28       Impact factor: 5.128

8.  Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.

Authors:  Janet M Soeffing; L David Martin; Michael I Fingerhood; Donald R Jasinski; Darius A Rastegar
Journal:  J Subst Abuse Treat       Date:  2009-06-23

9.  Redesigning the practice model for general internal medicine. A proposal for coordinated care: a policy monograph of the Society of General Internal Medicine.

Authors: 
Journal:  J Gen Intern Med       Date:  2007-03       Impact factor: 5.128

10.  A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension.

Authors:  Jacquelyn S Hunt; Joseph Siemienczuk; Ginger Pape; Yelena Rozenfeld; John MacKay; Benjamin H LeBlanc; Daniel Touchette
Journal:  J Gen Intern Med       Date:  2008-09-25       Impact factor: 5.128

View more
  105 in total

1.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

2.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

3.  Management of Opioid Misuse and Opioid Use Disorders Among Youth.

Authors:  Camille A Robinson; J Deanna Wilson
Journal:  Pediatrics       Date:  2020-05       Impact factor: 7.124

4.  Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial.

Authors:  Jane M Liebschutz; Ziming Xuan; Christopher W Shanahan; Marc LaRochelle; Julia Keosaian; Donna Beers; George Guara; Kristen O'Connor; Daniel P Alford; Victoria Parker; Roger D Weiss; Jeffrey H Samet; Julie Crosson; Phoebe A Cushman; Karen E Lasser
Journal:  JAMA Intern Med       Date:  2017-09-01       Impact factor: 21.873

5.  Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence.

Authors:  Ryan Schwarz; Alexei Zelenev; R Douglas Bruce; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2012-04-24

6.  Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.

Authors:  Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin
Journal:  J Gen Intern Med       Date:  2017-02-13       Impact factor: 5.128

7.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

8.  Emerging adult age status predicts poor buprenorphine treatment retention.

Authors:  Zev Schuman-Olivier; Roger D Weiss; Bettina B Hoeppner; Jacob Borodovsky; Mark J Albanese
Journal:  J Subst Abuse Treat       Date:  2014-05-20

9.  Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.

Authors:  Jane M Liebschutz; Denise Crooks; Debra Herman; Bradley Anderson; Judith Tsui; Lidia Z Meshesha; Shernaz Dossabhoy; Michael Stein
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

Review 10.  Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Authors:  E Jennifer Edelman; David A Fiellin
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.